Why the study?
Does recombinant human soluble thrombomodulin inhibit thrombus formation with less bleeding risk compared to heparin in a rat arteriovenous shunt thrombosis model?
Population
Rats with an arteriovenous shunt thrombosis model
Comparison
Intravenous administration of recombinant human… vs Heparin at 25-200 U/kg
Design
Preclinical
Authors
Loading...
Encourages clinical development of rhs-TM; leaves open translation from rat model to human thrombosis trials.
Does recombinant human soluble thrombomodulin inhibit thrombus formation with less bleeding risk compared to heparin in a rat arteriovenous shunt thrombosis model?
In a rat model, rhs-TM effectively inhibits thrombus formation with less APTT prolongation and less perturbation of hemostasis compared to heparin.
Aoki et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: